
Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.

Your AI-Trained Oncology Knowledge Connection!


Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.

Jamie Koprivnikar, MD, and Solly Chedid, MD, discuss ways to continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients.

Jamie Koprivnikar, MD, provides key takeaways for optimizing anemia management in patients with lower-risk MDS, highlighting unmet needs in treating anemia and improving patient outcomes.

An expert on the treatment of patients with myelodysplastic syndromes provides clinical insights on dosing practices and considerations for luspatercept.

Jamie Koprivnikar, MD, discusses factors that signal a need to transition a patient with lower-risk MDS from an ESA to another therapy.

Highlighting recent data from a post hoc analysis from the COMMANDS trial, a hematologist-oncologist offers insights on important factors to consider when assessing quality of life in patients with MDS.

Jamie Koprivnikar, MD, discusses how findings from the COMMANDS trial can be used to inform treatment decisions for patients based on serum EPO levels and the presence or absence of ring sideroblasts.

Focusing on molecular prognostic models in LR-MDS, Jamie Koprivnikar, MD, shares insights gleaned from the COMMANDS trial on how mutational burden impacts response.

A hematologist-oncologist provides expert perspectives on the development and implementation of the IPSS-M as a clinical-molecular prognostic model in lower-risk MDS.

Jamie L. Koprivnikar, MD, presents a case of a 70-year-old man with SF3B1+ MDS with ring sideroblasts and discusses the approach to initial therapy in patients with lower-risk MDS who may have moderate-to-severe anemia.

Drs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.

Clinicians review the MEDALIST trial, which evaluated luspatercept in the second-line setting and comment on updated data from MEDALIST that was recently presented at the annual ASH 2023 meeting.

Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.

Experts comment on factors that influence their decision-making when treating patients with lower-risk MDS.

Insights into treatment goals and review of the current treatment landscape for lower-risk MDS.

Clinicians discuss the importance of early detection in patients with MDS as well as providing insights into some of the unmet needs in MDS, such as a better understanding of the role of molecular alterations and its specific impact in MDS.

Hana Safah, MD explains how the risk stratification for MDS has evolved over time and provides an in-depth of the current risk stratification tools, IPSS, IPSS-R and IPSS-M.

Drs Safah and Koprivnikar review updates made to the WHO and ICC guidelines when classifying MDS as well as discussing the impact of molecular alterations when treating MDS.

Experts review best practices for identifying and diagnosing patients with lower-risk MDS.

Jamie L. Koprivnikar, MD, closes by sharing some future insights and remaining unmet needs for patients with myelodysplastic syndrome.

Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.

A review of the rationale and study design of the phase 3 COMMANDS trial and subsequent subgroup analysis data recently presented at the ASCO and EHA 2023 Annual Meetings.

Jamie L. Koprivnikar, MD, reviews luspatercept as a treatment option in myelodysplastic syndrome and the adverse events most frequently seen with her patients in clinical practice.

Dr Jamie L. Koprivnikar comments on the currently unmet needs for patients with low-risk myelodysplastic syndrome in the front-line setting.

Jamie L. Koprivnikar, MD, details how her treatment approaches differ for patients with low-risk versus high-risk myelodysplastic syndrome.

Dr Jamie L. Koprivnikar describes her general approaches to diagnosing and risk stratifying patients with myelodysplastic syndrome, and how she differentiates high-risk and low-risk disease.

Jamie L. Koprivnikar, MD, presents the case of a 72-year-old woman diagnosed with single lineage dysplasia myelodysplastic syndrome and shares her initial impressions.

Published: January 10th 2024 | Updated:

Published: January 18th 2024 | Updated:

Published: January 24th 2024 | Updated:

Published: September 22nd 2023 | Updated:

Published: September 8th 2023 | Updated:

Published: September 29th 2023 | Updated: